Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer

CAMBRIDGE, Mass. and NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced the promotion of Melanie Morrison from Senior Vice President, Development Operations to Chief Development Officer. As Chief Development Officer, Ms. Morrison leads the Company’s clinical operations, program management and program leadership functions, and regulatory affairs.

“Since joining the Company in 2022 as Senior Vice President, Development Operations, Melanie has demonstrated exceptional leadership and has played a critical role in advancing our clinical programs by leveraging her expertise in clinical-stage oncology development, operations and regulatory affairs. She has played an integral part in our Phase 1 trial for BDTX-1535 in non-small cell lung cancer and glioblastoma and I am extremely pleased to announce her well-deserved promotion to Chief Development Officer. I look forward to continuing to work with her alongside the rest of the executive leadership team as we move towards the initial clinical data update from the Phase 1 trial of BDTX-1535,” said David M. Epstein, Ph.D., President and Chief Executive Officer of Black Diamond Therapeutics. 

“The passion of the Black Diamond team is evidenced by their commitment to driving novel MasterKey inhibitors into the clinic for patients who are in serious need of new treatment options. I am excited to continue supporting the Company’s mission in this new role, as we work to overcome the limitations of existing therapies and fulfill the promise of precision oncology,” said Ms. Morrison.

Ms. Morrison joined Black Diamond in October 2022 with over two decades of experience in clinical operations, program management, product leadership and other key development functions in addition to driving corporate transitions from early to late-stage development at several biopharmaceutical companies. Prior to Black Diamond, Ms. Morrison was Senior Vice President, Program Management and Clinical Operations at Nuvation Bio, a clinical-stage oncology company, where she built and oversaw multiple groups within the development organization in support of Nuvation Bio’s pipeline. Previously she held program and clinical operations leadership roles at Aduro Biotech, Immune Design, and Medivation, where, prior to its acquisition by Pfizer, she was Vice President, Clinical Operations. Earlier in her career, Ms. Morrison held roles of increasing responsibility within the clinical operations and project management teams at Genentech focused on its oncology pipeline. She holds a Master of Science in Health Sciences from The George Washington University School of Medicine and Health Sciences and a Bachelor of Science from University of California, Davis.